Article Text

Download PDFPDF
Nicotine reduction revisited: science and future directions
  1. Dorothy K Hatsukami1,
  2. Kenneth A Perkins2,
  3. Mark G LeSage3,
  4. David L Ashley4,
  5. Jack E Henningfield5,
  6. Neal L Benowitz6,
  7. Cathy L Backinger7,
  8. Mitch Zeller8
  1. 1Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, USA
  2. 2Department of Psychiatry University of Pittsburgh, Pittsburgh, Pennsylvania, USA
  3. 3Department of Medicine, University of Minnesota Minneapolis Medical Research Foundation, Minneapolis, Minnesota, USA
  4. 4National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  5. 5Pinney Associates, Bethesda, Maryland, USA
  6. 6Department of Medicine and Bioengineering & Therapeutic Science, University of California, San Francisco, California, USA
  7. 7Tobacco Control Research Branch, National Cancer Institute, Rockville, Maryland, USA
  8. 8Pinney Associates, Bethesda, Maryland, USA
  1. Correspondence to Dorothy K Hatsukami, University of Minnesota, Tobacco Use Research Center, 717 Delaware St SE, Minneapolis, Minnesota 55414, USA; hatsu001{at}umn.edu

Footnotes

  • Funding National Institute on Drug Abuse, Rockville, Maryland, USA, National Cancer Institute, Rockville, Maryland, USA. Other Funders: American Legacy Foundation, Washington DC, USA.

  • Competing interests DKH has received grant funding from Nabi Biopharmaceuticals to conduct nicotine vaccine clinical trials. JEH provides consulting support for GlaxoSmithKline Consumer Health through Pinney Associates on an exclusive basis on issues related to tobacco dependence treatment, has financial interest in a potential new oral nicotine replacement product and serves as an expert witness in litigation against tobacco companies. NLB serves as a consultant for Pfizer and as an expert witness in litigation against tobacco companies. MZ provides consulting support to GlaxoSmithKline Consumer Health through Pinney Associates on an exclusive basis on issues related to tobacco dependence treatment. KAP has served as a consultant to Cypress Bioscience.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding National Institute on Drug Abuse, Rockville, Maryland, USA, National Cancer Institute, Rockville, Maryland, USA. Other Funders: American Legacy Foundation, Washington DC, USA.

  • Competing interests DKH has received grant funding from Nabi Biopharmaceuticals to conduct nicotine vaccine clinical trials. JEH provides consulting support for GlaxoSmithKline Consumer Health through Pinney Associates on an exclusive basis on issues related to tobacco dependence treatment, has financial interest in a potential new oral nicotine replacement product and serves as an expert witness in litigation against tobacco companies. NLB serves as a consultant for Pfizer and as an expert witness in litigation against tobacco companies. MZ provides consulting support to GlaxoSmithKline Consumer Health through Pinney Associates on an exclusive basis on issues related to tobacco dependence treatment. KAP has served as a consultant to Cypress Bioscience.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles